Anixa Biosciences and Moffitt Cancer Center Complete Dosing in Third Cohort in Ovarian Cancer CAR-T Clinical Trial [Yahoo! Finance]
Anixa Biosciences, Inc. (ANIX)
Last anixa biosciences, inc. earnings: 3/9 05:10 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
on the treatment and prevention of cancer, today announced has it has dosed its final patient in the third cohort of its ongoing Phase 1 clinical trial evaluating its novel chimeric antigen receptor-T cell (CAR-T) therapy for recurrent ovarian cancer. The study is being conducted through a research partnership with Moffitt Cancer Center ("Moffitt"). The fourth cohort is expected to commence after a 30-day verification that there continue to be no adverse effects experienced by the third cohort. Anixa Biosciences, Inc. (PRNewsfoto/Anixa Biosciences, Inc.) The third cohort in the trial received a dose of one million CAR-positive cells per kilogram of patient weight, which represents a tenfold increase compared to the first cohort. This escalation is an important step in evaluating the safety and efficacy of CAR-T therapy for ovarian cancer patients. The fourth cohort will increase the dosage by another factor of three. Anixa's FSHR-mediated CAR-T technology targets the follicle-st
Show less
Read more
Impact Snapshot
Event Time:
ANIX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANIX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANIX alerts
High impacting Anixa Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
ANIX
News
- Anixa Biosciences Announces Transfer of IND for Breast Cancer Vaccine from Cleveland Clinic [Yahoo! Finance]Yahoo! Finance
- Anixa Biosciences Announces Transfer of IND for Breast Cancer Vaccine from Cleveland ClinicPR Newswire
- Anixa Biosciences (NASDAQ:ANIX) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $10.00 price target on the stock.MarketBeat
- Anixa Biosciences Announces Positive Phase 1 Data for Investigational Breast Cancer Vaccine; Primary Endpoints Were Met and Immune Response Observed in 74% of Participants [Yahoo! Finance]Yahoo! Finance
- Anixa Biosciences Announces Positive Phase 1 Data for Investigational Breast Cancer Vaccine; Primary Endpoints Were Met and Immune Response Observed in 74% of ParticipantsPR Newswire
ANIX
Earnings
- 9/10/25 - Beat
ANIX
Sec Filings
- 12/16/25 - Form 4
- 12/12/25 - Form 8-K
- 10/31/25 - Form 4
- ANIX's page on the SEC website